CAR-T Therapy

Phase 1Cell therapy

UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology

CAR-T Therapy is one of 143 small molecule programs targeting Systemic Lupus Erythematosus. It is currently in Phase 1.

Indications

Total Trials

Active Trials

142

Competitors

Pipeline

Status by Indication[3][1]

Indication

Systemic Lupus ErythematosusActive, not recruiting

VasculitisActive, not recruiting

LymphomaActive, not recruiting

Acute Lymphoblastic LeukemiaActive, not recruiting

Systemic Lupus ErythematosusPhase 1

Active, not recruiting

VasculitisPhase 1

Active, not recruiting

LymphomaPreclinical

Active, not recruiting

Acute Lymphoblastic LeukemiaPhase 1

Active, not recruiting

Competition

Competitive Landscape

1774 competitors in Lymphoma

#DrugCompanyPhaseTrials

Blenoxane

SSequus Pharmaceuticals

Preclinical

25 2

Velban

EEastern Cooperative Oncology Group

Preclinical

15 3

Oncaspar

SServier

Preclinical

15 4

Norvir

AbbVie

Preclinical

1 5

Wellcovorin

GGlaxo Dba Glaxosmithkline

Preclinical

4 6

Nuvigil

NNuvo Research GmbH

Preclinical

1 7

Emend

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 8

Kenalog

BBausch Health Americas, Inc.

Preclinical

1 9

CAR-T Therapy

UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology

Phase 1

2 10

Systemic Therapy

Bristol-Myers Squibb

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1Recruiting

Systemic Lupus Erythematosus

NCT06822881

Phase 1Not yet recruiting

Refractory

NCT06647329

Q1 2027

Phase 1Recruiting

Refractory

NCT07031713

Phase 1Not yet recruiting

Vasculitis

NCT07033299

Q4 2027

Phase 1Recruiting

Treatment

NCT07280494

Q2 2028

Phase 1Recruiting

Acute Lymphoblastic Leukemia

NCT06752785

Clinical

Trials by Indication[1]

Lymphoma2 trials

Immunotherapy in Lymphoma

Recruiting·SSung-Soo Park··NCT06796517·72 enrolled

Clinical Study of CD7 CAR-T Cell Injection in the Treatment of Patients With Relapsed or Refractory CD7-positive Peripheral T Cell Lymphoma

Unknown status·ZZhao Weili·Phase 1·NCT05979792·35 enrolled

Refractory2 trials

CAR-T Technology for Recurrent/Refractory Malignant Hematological and Lymphatic Tumors

Not yet recruiting·MMingzhi Zhang·Phase 1·NCT06647329·30 enrolled

Safety, Efficacy and Cellular Metabolic Dynamics of ct1192 in Patients With Moderate to Severe Refractory SLE

Recruiting·UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology·Phase 1·NCT07031713·12 enrolled

Treatment Outcome1 trial

Quality of Life and Treatment Outcomes in RRMM Patients Receiving Advanced vs. Conventional Immunotherapies

Recruiting·SSung-Soo Park··NCT07051850·174 enrolled

Systemic Lupus Erythematosus1 trial

CT1190B in the Treatment of Patients With Moderate to Severe Refractory Systemic Lupus Erythematosus (SLE) or Refractory/Progressive Systemic Sclerosis (SSc)

Recruiting·—·Phase 1·NCT06822881·27 enrolled

Treatment1 trial

To Observe the CD7-targeted CAR-T Therapy in the Treatment of MRD Positive T-ALL/LBL Post Allo-HSCT

Recruiting·PPeking University People's Hospital·Phase 1·NCT07280494·18 enrolled

2 more indications

Acute Lymphoblastic Leukemia1 trial

CD19/CD22 CAR-T Cell Therapy in MRD-Positive B-lineage Acute Lymphoblastic Leukemia in Children.

Recruiting·GGuangzhou Women and Children's Medical Center·Phase 1·NCT06752785·10 enrolled

Vasculitis1 trial

The Safety, Efficacy, and Cellular Metabolic Kinetics of CT1192 in Treating Patients With Anti Neutrophil Cytoplasmic Antibody Associated Vasculitis

Not yet recruiting·UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology·Phase 1·NCT07033299·12 enrolled

Sources

References

[1]
ClinicalTrials.gov — 9 trial records for CAR-T Therapy. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — CAR-T Therapy compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for CAR-T Therapy. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Union Hospital, Tongji Medical College, Huazhong University of Science and Technology company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Cell therapy[2]
Highest Phase: Phase 1[1]
Company: UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology

CAR-T Therapy

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q1 2027

Q4 2027

Q2 2028

Trials by Indication[1]

Lymphoma2 trials

Refractory2 trials

Treatment Outcome1 trial

Systemic Lupus Erythematosus1 trial

Treatment1 trial

Acute Lymphoblastic Leukemia1 trial

Vasculitis1 trial

References

Drug Info

Quick Facts

Related News